Abstract library

209 results for "selection criteria".
#203 Liver and Liver-Pancreastransplantation in the Two-stage Treatment of Liver Metastasized Neuroendocrine Tumors of the Pancreas: About Three Cases
Introduction: Although liver transplantation is a valid option in the treatment of metastasized neuroendocrine tumors, it is not promoted because of a donor organ shortage and disappointing results in older series.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Geert Roeyen
Authors:
#530 Liver Transplantation for Metastatic Neuroendocrine Tumor: A Case Series and Proposed Selection Criteria
Introduction: Liver transplantation (LT) for neuroendocrine tumor (NET) metastases is associated with a high risk of tumor recurrence. Patient selection is the key to future success and its increased utilization.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Douglas Quan
Authors:
#1861 Surgical Strategies and Selection Criteria for Patients with Liver Metastasis from Neuroendocrine Tumors: Personal Experience.
Introduction: The role of surgical treatment of liver metastasis from neuroendocrine neoplasm(NET) is still a debated issue,and the management of these patients is entrusted to the practical experience of single centers.The main problem is that there are not available randomized trials comparing surgical resection to unthreated patients or other liver directed therapy.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Dr Bruno Pauletti
Authors:
#973 Toward a Preoperative Classification of Mesenteric Lymph Node Metastases for Better Selection of Carcinoid Tumors Before Radical Surgery
Introduction: Surgery for small bowel carcinoid (SBC) and lymph node (LN) metastases, when technically possible, represents the best therapy. However, surgical challenge is (i) not to recuse patients for false unresectable mesenteric artery invasion, and/or (ii) to avoid extensive small bowel resection.
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: MD PhD Reza Kianmanesh
Authors:
#2217 Prognostic Impact of CHOI Response Criteria Compared to RECIST in Grade 1-2 Advanced Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study-NCT02841865)
Introduction: Response Evaluation Criteria In Solid Tumors (RECIST) are not presumably the most optimal option for predicting the benefit of antiangiogenic drugs in neuroendocrine tumors (NETs), given that tumor shrinkage is not frequent, and qualitative changes in tumor tissues are to be expected.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: PhD Paula Jimenez-Fonseca
Authors:
#693 Histopathological Reporting of Neuroendocrine Tumors: A 4-Year Tertiary Referral Centre Experience
Introduction: Histopathological recognition of neuroendocrine tumors (NETs) is straightforward, however, sub-classification, grading and staging is challenging with frequently evolving pathological criteria.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: Dr Anna Karpathakis
Authors:
#11 Plasma chromogranin - A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Sara Massironi
Authors:
#74 Non-functioning pancreatic endocrine tumors: diagnostic criteria and surgical treatment
Introduction: Neuroendocrine tumors were considered rare tumors several years ago. Several reports published recently have observed increased incidence of NETs suggesting that NETs are more prevalent than previously reported. Non-functioning pancreatic endocrine tumors (NFPETs), better defined as non-hyperfunctioning, are characterized by the absence of clinical or biochemical evidence of hormone hypersecretion. From the clinical standpoint, NFPETs can be either occasionally encountered or manifest clinically similar pancreatic tumors. Since both NFPET treatment and prognosis significantly differ from that of ductal adenocarcinoma and other pancreatic malignant tumors, an accurate differential diagnosis is needed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Alexander Vladimir Kochatkov
Authors:
#354 Risk Stratification Using Octreotide Test For Patients With Gastro-Entero-Pancreatic Neuroendocrine Tumors: Results Of Prospective Validation Of The Test
Introduction: Criteria for treatment with somatostatin analogs (SSAs) of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are presence of somatostatin receptors, a positive Octreoscan® or hormonal decrement >50% after octreotide s.c. injection (octreotide test, OT). We demonstrated that a plasma CgA decrement >/=30% after OT is a selection criterion able to predict the clinical response to SSAs.
Conference:
Category: Basic
Presenting Author: Dr Roberta Elisa Rossi
Authors:
#617 Incidence and Geographic Distribution of Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs): A Systematic Review of the Literature
Introduction: Based on the literature, the world-wide incidence of neuroendocrine tumors (NETs) seems to be increasing, however, a systematic literature overview is lacking.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Antongiulio Faggiano
Authors: